/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE
U.S./
EDMONTON, May 24 /CNW/ - Ceapro Inc. (CZO - TSX Venture) announces that it has entered into a best efforts financing engagement letter with Northern Securities Inc. ("Northern") for a brokered private placement of units ("Units") in the aggregate amount of $2,000,000 (the "Offering"). Each Unit will consist of one common share and one half of one common share purchase warrant. Each Unit will be sold at a price of $0.31. Each whole warrant is exercisable into one common share, at an exercise price of $0.45, for a period of 20 months from the date of issuance of the warrants.
In connection with the Offering, Northern will receive on closing a cash commission of 7% of the gross proceeds and a number of broker warrants equal to 7% of the number of Units sold under the Offering. Each broker warrant will entitle the holder thereof to acquire one Unit at the price of $0.31 for a period of 20 months from the date of issuance of the broker warrants. The Corporation has also granted Northern an over-allotment option ("Over- Allotment Option") to increase the size of the Offering by an aggregate amount of $1,000,000. President List Orders may also increase the size of the Offering up to an additional $500,000 for aggregate proceeds of $3,500,000.
The net proceeds of the Offering will be used for sales and marketing, research and development, product and market expansion, general corporate and working capital purposes.
Closing of the Offering is expected to occur on or about June 22, 2007. The completion of the Offering is subject to the approval of the TSX-Venture Exchange and other regulatory approval.
About Ceapro Inc.
Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc. and Ceapro Bioenergy Inc. are wholly owned subsidiaries of Ceapro Inc., which is a Canadian growth-stage biotechnology company. Our primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will be applying our technology to become an active participant in the bio-energy sector. We have also introduced health and wellness services employing our CeaProve(R) diagnostic technology.
The TSX has neither approved nor disapproved of the information contained
herein -
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement
%SEDAR: 00010110E